The switch from total cholesterol to non-HDLc—and the gradual inclusion of apoB in the standard lipid panel assessment—is explained by multiple studies that have shown the impact of triglyceride-rich lipoproteins, still atherogenic, on the development of ASCVD, especially in patients with obesity, metabolic syndrome, prediabetes or type 2 DM, diseases in which the assessment of the LDLc on its own could underestimate the impact of the lipid imbalance or the impact of the treatment in the primary- or secondary-CV prevention [27,28]. The gene discussed is APOB; the disease is Obesity.